EXACT Sciences Corp. (EXAS)

42.37
NASDAQ : Health Technology
Prev Close 44.99
Day Low/High 38.88 / 42.65
52 Wk Low/High 19.91 / 63.60
Avg Volume 2.34M
Exchange NASDAQ
Shares Outstanding 119.73M
Market Cap 5.58B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tripadvisor Inc , according to The Online Investor.

EXACT Sciences: Wait For a Better Buying Opportunity

EXACT Sciences: Wait For a Better Buying Opportunity

The stock still looks vulnerable to further declines from a technical perspective.

Exact Sciences: Cramer's Top Takeaways

Exact Sciences: Cramer's Top Takeaways

Kevin Conroy, chairman and CEO of Exact Sciences, tells Jim Cramer about his company's expansion plans for cancer screening tests.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Exact Sciences To Report $265.5-266.5 Million In Revenue, 168 Percent Growth For 2017

Exact Sciences To Report $265.5-266.5 Million In Revenue, 168 Percent Growth For 2017

- Preliminary 2017 revenue between $265.5 million and $266.5 million, a year-over-year increase of 168 percent

Exact Sciences To Expand Laboratory And Corporate Facilities In Madison

Exact Sciences To Expand Laboratory And Corporate Facilities In Madison

World-class lab and office space to support demand for Cologuard

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exact Sciences, Cognizant Technology, MetLife, JPMorgan Chase and more.

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment is critical to the next market move, says Jim Cramer. A little negativity is great news for the bulls.

Noteworthy Monday Option Activity: EXAS, SHAK, ETM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 9,758 contracts has been traded thus far today, a contract volume which is representative of approximately 975,800 underlying shares (given that every 1 contract represents 100 underlying shares).

Short Interest Drops 32.5% For EXAS

Short Interest Drops 32.5% For EXAS

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,295,292 share decrease in total short interest for EXACT Sciences Corp. , to 10,994,802, a decrease of 32.51% since 09/15/2017.

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Analysts, consultants and Shopify users came to the company's defense when TheStreet reached out to them.

Short Interest Declines 11.3% For EXAS

Short Interest Declines 11.3% For EXAS

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,075,458 share decrease in total short interest for EXACT Sciences Corp. , to 16,290,094, a decrease of 11.30% since 08/31/2017.

Short Interest Falls 11.2% For EXAS

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,304,856 share decrease in total short interest for EXACT Sciences Corp. , to 18,237,019, a decrease of 11.22% since 07/14/2017.

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Venture Capital firm Benchmark reiterated its 'Buy' rating on the stock and $50 price target.

Short Interest Moves 10% Lower For EXAS

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 2,463,634 share decrease in total short interest for EXACT Sciences Corp. , to 22,030,168, a decrease of 10.06% since 05/31/2017.

Jerry Kelly And Exact Sciences Team Up To Promote Colon Cancer Screening

Golfer launches multi-year, CologuardĀ®-branded campaign

Exact Sciences Stock Falls on Secondary Stock Sale

Exact Sciences Stock Falls on Secondary Stock Sale

The secondary offering, to be underwritten by Jefferies, Bank of America/Merrill Lynch and Robert W. Baird, would offer 7 million shares.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

TheStreet Quant Rating: D (Sell)